StemCells, Inc. (NASDAQ:STEM)
| CAPS Rating |
|
|---|---|
| Open | $1.00 |
| Previous Close | $1.01 |
| Daily Range | $0.98 - $1.03 |
| 52-Week Range | $0.70 - $9.82 |
| Market Cap | $13.88M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 260,342 |
| Average Daily Volume | 0 |
STEM
VS S&P 500 (SPY)
How do you think STEM will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
STEM Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
STEM News and Commentary
- Buy, Sell, or Hold: Geron – The Motley Fool
- The focus will be on Stem Cells again.. – Blog at The Motley Fool
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- When Giving Up Is a Good Move in Biotech – The Motley Fool
- Stem-Cell Stocks May Now Be Worth The Risk – SmartMoney
- Stinky Bottoms – Blog at The Motley Fool
- One Stem Cell Stock to Avoid – The Motley Fool
- 19 Micro Cap Stocks Being Dumped by Mutual Funds – SeekingAlpha
- StemCells Up for All the Right Reasons – The Motley Fool
- Wall Street's Best Hidden Stocks – The Motley Fool
- Hidden Stocks for High Returns – The Motley Fool
- Study Shows Cytori's Stem Cell Breast Reconstruction Is Safe – SmartMoney
- These Cold Stocks Are Heating Up – The Motley Fool
- Time to Buy Into Stem Cells? – The Motley Fool
- Just One Stock: The Biopharma Veteran Facing a Landmark Stem Cell Trial – SeekingAlpha
- Aastrom Biosciences' Uptrend Fueled by More Than Just Market Momentum – SeekingAlpha
- 3 Technology Sector Picks for 2011 – SeekingAlpha
- Cephalon's Foray Into Stem Cells Therapeutic Market – SeekingAlpha
- Is Geron the Perfect Stock? – The Motley Fool
RSS Headlines
Fool UK
